The California HIV/AIDS Research Program (CHRP) is proud to be funding the largest demonstration project of its kind in the U.S., to determine the acceptability, utilization, adherence, and pharmacokinetics of HIV pre-exposure prophylaxis (PrEP) medication among transgender persons.
In this new video, researchers, consumers, and health care providers offer their perspectives on why this research is important, and how members of the community can participate.
CHRP has invested $9.4 million in three research studies across the state, recognizing that the people in the transgender community deserve dedicated and substantial resources to promote their health and protect their lives. The studies each use different techniques, such as providing PrEP and hormonal therapy together at a single clinic visit, or an in-depth pharmacokinetic analysis to determine whether the two treatments interact, or a custom text messaging app to communicate with providers and offer peer support.
CHRP is grateful to the organizers of the National Transgender Health Summit for premiering this video at the opening plenary on November 11, 2017, in Oakland, California.